Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1951 2
1970 2
1971 1
1972 2
1975 1
1978 1
1979 1
1982 1
1987 1
1989 1
1991 1
1992 3
1993 1
1994 2
1995 3
1996 4
1997 5
1998 6
1999 5
2000 4
2001 4
2002 4
2003 5
2004 1
2005 2
2006 3
2008 3
2009 3
2010 3
2011 7
2012 6
2013 5
2014 12
2015 16
2016 19
2017 15
2018 18
2019 16
2020 23
2021 7
2022 9
2023 19
2024 17
2025 12

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

253 results

Results by year

Filters applied: . Clear all
Page 1
Dexmedetomidine for dyspnoea.
Mano A, Murata T, Date K, Kawata M, Sato M, Yamashita N, Iino K, Kyo S, Saito E. Mano A, et al. Among authors: date k. BMJ Support Palliat Care. 2023 Oct;13(e1):e84-e85. doi: 10.1136/bmjspcare-2020-002334. Epub 2020 Jun 11. BMJ Support Palliat Care. 2023. PMID: 32527791
Metabolic reprogramming by mutant GNAS creates an actionable dependency in intraductal papillary mucinous neoplasms of the pancreas.
Makino Y, Rajapakshe KI, Chellakkan Selvanesan B, Okumura T, Date K, Dutta P, Abou-Elkacem L, Sagara A, Min J, Sans M, Yee N, Siemann MJ, Enriquez J, Smith P, Bhattacharya P, Kim M, Dede M, Hart T, Maitra A, Thege FI. Makino Y, et al. Among authors: date k. Gut. 2024 Dec 10;74(1):75-88. doi: 10.1136/gutjnl-2024-332412. Gut. 2024. PMID: 39277181 Free PMC article.
YAP Regulates HER3 Signaling-Driven Adaptive Resistance to RET Inhibitors in RET-Aberrant Cancers.
Katayama Y, Yamada T, Tanimura K, Kawachi H, Ishida M, Matsui Y, Hirai S, Nakamura R, Morimoto K, Furuya N, Arai S, Goto Y, Sakata Y, Nishino K, Tsuchiya M, Tamiya A, Saito G, Muto S, Takeda T, Date K, Fujisaka Y, Watanabe S, Fujimoto D, Uehara H, Horinaka M, Sakai T, Yano S, Tokuda S, Takayama K. Katayama Y, et al. Among authors: date k. Clin Cancer Res. 2025 Mar 17;31(6):1127-1141. doi: 10.1158/1078-0432.CCR-24-1762. Clin Cancer Res. 2025. PMID: 39495173
Exploration of clinical Biomarkers for guiding treatment selection between chemotherapy and combination therapy with Atezolizumab, Bevacizumab, Carboplatin, and Paclitaxel in EGFR-Mutant NSCLC patients after EGFR-TKI Therapy: The SPIRAL-STEP study.
Morimoto K, Yamada T, Furuya N, Tanaka H, Yoshimura A, Oba T, Hibino M, Fukuda T, Goto Y, Nakao A, Ogusu S, Okazaki Y, Harada T, Ota T, Masubuchi K, Mikami K, Hata T, Matsumoto S, Honda R, Date K, Chihara Y, Takayama K. Morimoto K, et al. Among authors: date k. Lung Cancer. 2025 Mar;201:108447. doi: 10.1016/j.lungcan.2025.108447. Epub 2025 Feb 15. Lung Cancer. 2025. PMID: 39970730
Typhoid fever vaccination strategies.
Date KA, Bentsi-Enchill A, Marks F, Fox K. Date KA, et al. Vaccine. 2015 Jun 19;33 Suppl 3(Suppl 3):C55-61. doi: 10.1016/j.vaccine.2015.04.028. Epub 2015 Apr 19. Vaccine. 2015. PMID: 25902360 Free PMC article. Review.
Clinical impact of cancer cachexia on the outcome of patients with non-small cell lung cancer with PD-L1 tumor proportion scores of ≥50% receiving pembrolizumab monotherapy versus immune checkpoint inhibitor with chemotherapy.
Kawachi H, Yamada T, Tamiya M, Negi Y, Kijima T, Goto Y, Nakao A, Shiotsu S, Tanimura K, Takeda T, Okada A, Harada T, Date K, Chihara Y, Hasegawa I, Tamiya N, Katayama Y, Nishioka N, Morimoto K, Iwasaku M, Tokuda S, Shimose T, Takayama K. Kawachi H, et al. Among authors: date k. Oncoimmunology. 2025 Dec;14(1):2442116. doi: 10.1080/2162402X.2024.2442116. Epub 2024 Dec 16. Oncoimmunology. 2025. PMID: 39681395 Free PMC article.
Concomitant Proton Pump Inhibitor Use With Pembrolizumab Monotherapy vs Immune Checkpoint Inhibitor Plus Chemotherapy in Patients With Non-Small Cell Lung Cancer.
Kawachi H, Yamada T, Tamiya M, Negi Y, Goto Y, Nakao A, Shiotsu S, Tanimura K, Takeda T, Okada A, Harada T, Date K, Chihara Y, Hasegawa I, Tamiya N, Ishida M, Katayama Y, Morimoto K, Iwasaku M, Tokuda S, Kijima T, Takayama K. Kawachi H, et al. Among authors: date k. JAMA Netw Open. 2023 Jul 3;6(7):e2322915. doi: 10.1001/jamanetworkopen.2023.22915. JAMA Netw Open. 2023. PMID: 37432682 Free PMC article.
Unraveling the influence of TTF-1 expression on immunotherapy outcomes in PD-L1-high non-squamous NSCLC: a retrospective multicenter study.
Nishioka N, Kawachi H, Yamada T, Tamiya M, Negi Y, Goto Y, Nakao A, Shiotsu S, Tanimura K, Takeda T, Okada A, Harada T, Date K, Chihara Y, Hasegawa I, Tamiya N, Masui T, Sai N, Ishida M, Katayama Y, Morimoto K, Iwasaku M, Tokuda S, Kijima T, Takayama K. Nishioka N, et al. Among authors: date k. Front Immunol. 2024 Jul 15;15:1399889. doi: 10.3389/fimmu.2024.1399889. eCollection 2024. Front Immunol. 2024. PMID: 39076994 Free PMC article.
Depth of response and treatment outcomes of immune checkpoint inhibitor-based therapy in patients with advanced non-small cell lung cancer and high PD-L1 expression: An exploratory analysis of retrospective multicenter cohort.
Tachibana Y, Morimoto K, Yamada T, Kawachi H, Tamiya M, Negi Y, Goto Y, Nakao A, Shiotsu S, Tanimura K, Takeda T, Okada A, Harada T, Date K, Chihara Y, Hasegawa I, Tamiya N, Katayama Y, Nishioka N, Iwasaku M, Tokuda S, Kijima T, Takayama K. Tachibana Y, et al. Among authors: date k. Invest New Drugs. 2024 Oct;42(5):538-546. doi: 10.1007/s10637-024-01467-7. Epub 2024 Aug 21. Invest New Drugs. 2024. PMID: 39168900
253 results